Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong.
Chan HL, Tsang OT, Hui YT, Fung J, Lui GC, Lai CL, Wong GL, Chan KH, But DY, Lai MS, Lao WC, Chan CK, Lam YS, Seto WK, Li C, Yuen MF, Wong VW.
Chan HL, et al. Among authors: lui gc.
J Gastroenterol Hepatol. 2017 Jun;32(6):1230-1233. doi: 10.1111/jgh.13663.
J Gastroenterol Hepatol. 2017.
PMID: 27869328